SECTIONS
Home
Markets
Companies
Economy
Tech
Auto
Mutual Funds
Stocks
Currency
Opinions
More
Columnist: Jayati Ghose
New medical marvel: Firms have different prices for same drug
New medical marvel: Firms have different prices for same drug
Pharma Inc prepares to scale patent cliff, eyes $50-billion market
Pharma Inc prepares to scale patent cliff, eyes $50-billion market
Pharma Inc prepares to scale patent cliff, eyes $50-billion market
Pharma Inc prepares to scale patent cliff, eyes $50-billion market
DoTs doubts on shareholding change in BWA firm may hit Airtel-Qualcomm
Decks cleared for Rs 5,500-crore FDI boost to brownfield pharma projects
Liquid Dettol price likely to rise as pharma dept orders review of price cap
Liquid Dettol price likely to rise as pharma dept orders review of price cap
Half of global workforce in India, Mylan tells DIPP
Half of global workforce in India, Mylan tells DIPP
Half of global workforce in India, Mylan tells DIPP
Packaging defect prompts recall of Torrent Pharmaceuticals' anti-psychotic drug in US
Packaging defect prompts recall of Torrent Pharmaceuticals' anti-psychotic drug in US
PSUs need booster vaccine but govt puts Mylan on hold
Govt flip-flop on drugs ban prompts demand for stricter rules
Govt flip-flop on drugs ban prompts demand for stricter rules
Drug of war: Centre against companies' move to sell old stocks at above-ceiling rates
Drug of war: Centre against companies' move to sell old stocks at above-ceiling rates
Drug of war: Centre against companies' move to sell old stocks at above-ceiling rates
Free mobile phone scheme back on table
Free mobile phone scheme back on table
Free mobile phone scheme back on table
FIPB clears 6 brownfield pharma FDI proposals
Drug cos' contingent liabilities on overcharging seen close to Rs10k cr
Drug cos' contingent liabilities on overcharging seen close to Rs10k cr
Abbott to bank on localised innovation for India growth
Abbott to bank on localised innovation for India growth
New rules may boost clinical trials
New rules may boost clinical trials
SC upholds price ceiling for asthma drug
Govt may relax norms for brownfield pharma FDI
Prices of important drugs may be halved as govt set to notify rate caps
Prices of important drugs may be halved as govt set to notify rate caps
Prices of important drugs may be halved as govt set to notify rate caps
Issuance of Form 483 by USFDA not a show-stopper
Mylans Agila stride to open FDI floodgates
Mylans Agila stride to open FDI floodgates
Drug price ceiling to be revised with fresh data
In India, copycat drug firms get off lightly compared with US
In India, copycat drug firms get off lightly compared with US
Method to fix drug price cap kicks up controversy
Method to fix drug price cap kicks up controversy
In India, copycat drug firms get off lightly compared with US
Domestic drug prices immune to pharma acquisitions
Domestic drug prices immune to pharma acquisitions
DoT may go for allotment route instead of auction for some spectrum
Getting off FDA watch list a long haul for Ranbaxy
DoT looks to use white spaces for Wi-Fi
Pfizer, domestic pharma body lock horns over Indian IP laws
Ranbaxy sold new drugs without nod, says USFDA plaint
FDA's 2009 Ranbaxy Laboratories letter sealed Malvinder Singhs fate
FDA's 2009 Ranbaxy Laboratories letter sealed Malvinder Singhs fate
FDA crackdown on Indian drug firms no witch hunt
FDA crackdown on Indian drug firms no witch hunt
FDA crackdown on Indian drug firms no witch hunt
IPA slams Pfizers testimony to panel
A few hundred inspectors for 10,500 drug units
Malvinder Singh lashes out at Daiichi Sankyo, says 'They didn't run Ranbaxy Laboratories Limited well, now they blame me'
Malvinder Singh lashes out at Daiichi Sankyo, says 'They didn't run Ranbaxy Laboratories Limited well, now they blame me'
Malvinder Singh lashes out at Daiichi Sankyo, says 'They didn't run Ranbaxy Laboratories Limited well, now they blame me'
DG Audit calls up DoT, says telcos not adhering to service standards
Pharma Inc relies on China for API needs
Shinde to scout for tech at US security dialogue
Chinese firms dominate telecom & power sectors
Chinese firms dominate telecom & power sectors
Relaxing alternative therapy, but painful insurance claim
Relaxing alternative therapy, but painful insurance claim
Act on Tata Tele or face legal action, COAI warns DoT
Act on Tata Tele or face legal action, COAI warns DoT
Law min to vet norms for unified telecom licence
US marketing to get tough for Ranbaxy Laboratories Limited
US marketing to get tough for Ranbaxy Laboratories Limited
Drug bans All talk, no walk
Clinical trials Swallowing a bitter-sweet pill
A cure for Pills
Security body bats for UK model to test imported telecom gear for bugs
Security body bats for UK model to test imported telecom gear for bugs
Proposal to fix pricing of patented drugs back on govt drawing board
Indian pharmas R&D magic pill turns out to be a placebo
India wants EU to stop seizure of generic drugs
Drug majors may not get nod to raise insulin rates
Security sensitive telecom gear must be made in India, says DoT
DRL likely to capture 50% of Latuda market
PM clears ministers committee to study BSNL, MTNL revival
DoT to form panel to look at green tower funding
'New norms won't lead to rise in drug prices for a year'
'New norms won't lead to rise in drug prices for a year'
'New norms won't lead to rise in drug prices for a year'
'New norms won't lead to rise in drug prices for a year'
Many top-selling drugs to cost less in new regime
Unified licence rules by month end
MSD-Glenmark case replay of Bayer-Cipla patent feud
Montek favours spectrum trade, wants Trai to examine feasibility
Sibal taps PM, seeks intensive care treatment for ailing telecom PSUs
System lacuna a bitter pill for patent holders
System lacuna a bitter pill for patent holders
System lacuna a bitter pill for patent holders
Pharma giants may go slow on Indian R&D
Tweets by FinancialXpress
